KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.

Hyun Cheol  Chung

Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celltrion; Celltrion; Celltrion; Celltrion; Gloria Biosciences; Gloria Biosciences; Gloria Biosciences; Gloria Biosciences; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Quintiles; Quintiles; Quintiles; Quintiles; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical

Speakers' Bureau - Foundation medicine; Foundation medicine; Foundation medicine; Foundation medicine; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono

Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical

Yung-Jue  Bang

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genexine; Genexine; Genexine; Genexine; Green Cross; Green Cross; Green Cross; Green Cross; Hanmi; Hanmi; Hanmi; Hanmi; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; Samyang; Samyang; Samyang; Samyang; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Chong Kun Dang Pharmaceutical (Inst); Chong Kun Dang Pharmaceutical (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Curis (Inst); Curis (Inst); Curis (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genexine (Inst); Genexine (Inst); Genexine (Inst); Genexine (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Green Cross (Inst); Green Cross (Inst); Green Cross (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)

Charles S.  Fuchs

Leadership - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics

Stock and Other Ownership Interests  - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health

Consulting or Advisory Role - Agios; Agios; Agios; Agios; Bain Capital; Bain Capital; Bain Capital; Bain Capital; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Dicerna; Dicerna; Dicerna; Dicerna; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; KEW; KEW; KEW; KEW; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics

Shukui  Qin

No Relationships to Disclose

Taroh  Satoh

Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha

Consulting or Advisory Role - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Takara Bio; Takara Bio; Takara Bio; Takara Bio

Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)

Kohei  Shitara

Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Novartis; Novartis; Novartis; Novartis; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Takeda; Takeda; Takeda; Takeda

Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)

Josep  Tabernero

Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Genmab; Genmab; Genmab; Genmab; HalioDx; HalioDx; HalioDx; HalioDx; Halozyme; Halozyme; Halozyme; Halozyme; Imugene; Imugene; Imugene; Imugene; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Ipsen; Ipsen; Ipsen; Ipsen; Kura Oncology; Kura Oncology; Kura Oncology; Kura Oncology; Lilly; Lilly; Lilly; Lilly; Menarini; Menarini; Menarini; Menarini; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merrimack; Merrimack; Merrimack; Merrimack; Merus; Merus; Merus; Merus; Molecular Partners; Molecular Partners; Molecular Partners; Molecular Partners; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Peptomyc; Peptomyc; Peptomyc; Peptomyc; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; ProteoDesign; ProteoDesign; ProteoDesign; ProteoDesign; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Servier; Servier; Servier; Servier; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; VCN Biosciences; VCN Biosciences; VCN Biosciences; VCN Biosciences

Eric  Van Cutsem

Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER

Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst)

Maria  Alsina

No Relationships to Disclose

Z. Alexander  Cao

Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Merck; Merck; Merck; Merck

Stock and Other Ownership Interests  - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck

Xinqun  Chen

Employment - Merck; Merck; Merck; Merck

Stock and Other Ownership Interests  - Merck; Merck; Merck; Merck

Pooja  Bhagia

No Relationships to Disclose

Chie-Schin  Shih

Employment - Merck; Merck; Merck; Merck

Research Funding - Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst)

Travel, Accommodations, Expenses - Exelixis; Exelixis; Exelixis; Exelixis

Yelena Yuriy  Janjigian

Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Michael J. Hennessy Associates; Michael J. Hennessy Associates; Michael J. Hennessy Associates; Michael J. Hennessy Associates; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Rgenix; Rgenix; Rgenix; Rgenix

Research Funding - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Genentech; Genentech; Genentech; Genentech; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche